CNS & Neurotherapeutics Innovators

Neurological and neuropsychiatric therapies are entering a multi-year commercial wave driven by new drug delivery technologies, subcutaneous reformulations, and regulatory momentum across schizophrenia, depression, and movement disorders. Fresh approvals illustrate how differentiated delivery mechanisms create sticky, long-cycle franchises independent of broader macroeconomic trends. This basket targets biopharma companies with commercialized drugs and late-stage development pipelines focused squarely on central nervous system disorders. Catalysts: - 2026-10-09 TEVA wins FDA approval for monthly schizophrenia injection Weltruza (https://www.reuters.com/legal/litigation/teva-wins-fda-approval-monthly-schizophrenia-injection-weltruza-2026-10-09/) Launch basket (equal weight): ABBV, BMRN, LLY, JPM, MRK, AMGN, TMO, TEVA Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.